Amgen Faces Potential EU Withdrawal of Tavneos Due to Data Integrity Issues
An expert panel from the European Medicines Agency recommended revoking Amgen's marketing authorization for its rare-disorder therapy, Tavneos, in the EU due to data integrity concerns. This decision could lead to a potential withdrawal of the drug in Europe.
Tickers: $AMGN
Topics: pharmaceuticals rare diseases regulation